Compound Profiling and Screening Services
Promega empowers R&D innovators with a one-stop solution for assays, cutting-edge bioluminescent and fluorescent technologies, and state-of-the-art automation to accelerate drug discovery. Our expert team provides flexible, high-quality, reproducible data tailored to your needs, supplementing existing capacity and delivering time and cost savings.
From high-throughput screening to selectivity profiling, we leverage advanced cellular technologies and target-based assays to deliver actionable insights that streamline your drug discovery journey. Whether identifying initial hits or optimizing leads, our tailored solutions ensure your therapeutic innovations progress efficiently, accelerating their path to market.
Overview
Our compound profiling services deliver precision, reliability and insightful data critical for advancing drug development. Our cutting-edge bioluminescent and fluorescent technologies provide deep insights into the pharmacodynamics, mechanism of action and potential off-target effects of compounds. This comprehensive understanding allows you to make informed decisions, optimize your lead candidates and mitigate risks early in the development process. With Promega, you gain a trusted partner that enhances your ability to bring safer, more effective therapeutic solutions to market quicker.
Capabilities
- Single point and dose-response curves
- >300 validated target engagement assays
- >130 degradation assays using CRISPR HiBiT KI cell lines
- Amenable to custom targets and other Promega technologies (protein:protein interaction assays, bioassays, etc.)
Automated Data Processing
- Automated data analysis, QC and report generation
Resources
- Dedicated team of scientists
State-of-the-Art Instrumentation
- HighRes Bioscience AC2 Robotic System
- >30k datapoints per day
What Services Do We Offer?
Our compound profiling services focus on three key areas: kinase target engagement, target engagement with other key drug targets, and targeted protein degradation.
Kinase Target Engagement
- NanoBRET® Target Engagement technology provides quantitative measurements in live cells
- Comprehensive panels spread across the kinome (192 and 240 full-length kinases)
- Custom options available
Learn more about our kinase selectivity profiling services.
Key Drug Targets
- Kinase Panels
- RAS/RAF Pathways: live-cell assays available for RAS, RAF, MEK, ERK proteins
- PARP Family: panel covers 12 of 17 PARPs
- E3 Ligases: assays available for CRBN, VHL, XIAP, cIAP, MDM2
- BET BRD: assays available for BRD2 FL, BRD2 BD1, BRD2 BD2, BRD3 FL, BRD4 FL, BRD4 BD1, BRD4 BD2, BRDT FL
- NLRP3 Inflammasome: measure inhibitor binding and detect NLRP3 activation state in live cells
- Custom options available
Targeted Protein Degradation
- Protein degradation
- Neosubstrates
- Mechanistic assays
- Custom options available
Why Choose Promega?
We help you succeed with our collaborative approach, innovative technologies and commitment to high quality standards.
- Trusted NanoBRET® Target Engagement technology
- Cellular assay provides biologically relevant results
- Close collaboration with our scientists from start to finish
- Typical turn-around time: 2–3 weeks
Your Data
- Quantitative measurement of compound affinity and occupancy in live cells
- Includes cellular selectivity and off-target activity
- Ratiometric BRET data provide reproducibility with low error rates
- Both single-point and dose-response data with technical duplicates
Custom Options
- Custom-built assays: Don’t see your favorite target on our list? Inquire about our ability to profile against your favorite target(s).
- Residence time kinetic measurement
Overview
Our high-throughput screening (HTS) services enable you to efficiently screen entire compound libraries or select subsets against our proven suite of technologies. With our advanced platforms, you can rapidly evaluate thousands of compounds for activity and specificity. This streamlined process not only accelerates the identification of viable drug candidates but also integrates seamlessly with our array of bioluminescent and fluorescent assays, ensuring precise, reproducible results that drive forward the most promising leads in drug development projects.
What Services Do We Offer?
HTS campaigns that are flexible in scale and format, from focused libraries to large diversity sets:
- Capacity to screen 30k compounds per day
- Customer- or vendor-supplied libraries
Leverage any Promega assay technology, including:
- NanoBRET® Target Engagement
- Protein degradation (using HiBiT technology)
- Protein:protein interactions (using NanoBRET®, NanoBiT® or Lumit® technologies)
- Lumit® Immunoassays
Assay development and validation on automation:
- Leverage technology experts in R&D
